Skip to content

Cogent Biosciences, Inc. COGT Gain (loss) on extinguishment of debt

Gain (loss) on extinguishment of debt at other companies

Scholar Rock logo
Scholar RockSRRK
-$3.34M
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$0+100%
TG Therapeutics logo
TG TherapeuticsTGTX

Other financials

Income statement

See full
Operating income-$103.6M-38.3%
Net income-$97.4M-35.2%
EPS (diluted)-$0.53-1.9%

Balance sheet

See full
Cash & equivalents$241.2M+91.4%
Total debt$15.5M-9.4%
Total equity$607.7M+177%
Total assets$903.0M+218%

Cash flow

See full
Operating cash flow-$86.9M-30.6%
CapEx$449.0K-17.9%
Free cash flow-$87.3M-30.2%

Valuation

See full
Market cap$5.9B+816%
Enterprise value$5.68B+951%
P/S749.8×

Profitability

See full
Operating margin-1,044.3%
Net margin-950.4%
FCF margin-184.7%

Returns & leverage

See full
Return on equity-85.7%+1.7pp
Debt / equity-0.1×
Current ratio15.1×+10.0×

Where this comes from

Reported directly by Cogent Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GainsLossesOnExtinguishmentOfDebt.

The official record: Cogent Biosciences, Inc.’s 10-K, filed February 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cogent Biosciences, Inc.'s gain (loss) on extinguishment of debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cogent Biosciences, Inc.'s gain (loss) on extinguishment of debt?
Cogent Biosciences, Inc. (COGT) reported gain (loss) on extinguishment of debt of -$1.8M in Q4 2025.
What does gain (loss) on extinguishment of debt mean?
Gains or losses from retiring debt before maturity — gains when debt is repurchased below par, losses when premiums are paid for early redemption.